EP1061800A4 - Compositions and methods for modulating vascularization - Google Patents

Compositions and methods for modulating vascularization

Info

Publication number
EP1061800A4
EP1061800A4 EP99912344A EP99912344A EP1061800A4 EP 1061800 A4 EP1061800 A4 EP 1061800A4 EP 99912344 A EP99912344 A EP 99912344A EP 99912344 A EP99912344 A EP 99912344A EP 1061800 A4 EP1061800 A4 EP 1061800A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
vascularization
modulating
modulating vascularization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99912344A
Other languages
German (de)
French (fr)
Other versions
EP1061800A1 (en
Inventor
Jeffrey M Isner
Takayuki Asahara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St Elizabeths Medical Center of Boston Inc
Original Assignee
St Elizabeths Medical Center of Boston Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St Elizabeths Medical Center of Boston Inc filed Critical St Elizabeths Medical Center of Boston Inc
Publication of EP1061800A1 publication Critical patent/EP1061800A1/en
Publication of EP1061800A4 publication Critical patent/EP1061800A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP99912344A 1998-03-09 1999-03-09 Compositions and methods for modulating vascularization Withdrawn EP1061800A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7726298P 1998-03-09 1998-03-09
US77262P 1998-03-09
PCT/US1999/005130 WO1999045775A1 (en) 1998-03-09 1999-03-09 Compositions and methods for modulating vascularization

Publications (2)

Publication Number Publication Date
EP1061800A1 EP1061800A1 (en) 2000-12-27
EP1061800A4 true EP1061800A4 (en) 2004-10-06

Family

ID=22137044

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99912344A Withdrawn EP1061800A4 (en) 1998-03-09 1999-03-09 Compositions and methods for modulating vascularization

Country Status (5)

Country Link
EP (1) EP1061800A4 (en)
JP (2) JP2002506008A (en)
AU (1) AU766238B2 (en)
CA (1) CA2322559C (en)
WO (1) WO1999045775A1 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094420A1 (en) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
IL153115A0 (en) * 2000-06-16 2003-06-24 Curis Inc Angiogenesis-modulating compositions and uses
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7547674B2 (en) * 2001-06-06 2009-06-16 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002022163A1 (en) 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedies for ischemic diseases
AU2002227425B2 (en) * 2000-10-30 2005-10-20 Children's Medical Center Corporation Tissue-engineered vascular structures
CA2467557A1 (en) * 2001-11-19 2003-05-30 Kyowa Hakko Kogyo Co., Ltd. Agent which mobilizes multipotential stem cells from tissues to peripheral blood
WO2003059375A1 (en) * 2002-01-17 2003-07-24 Cardio Incorporated Complex therapy for tissue regeneration
KR100562824B1 (en) 2002-03-20 2006-03-23 주식회사 바이로메드 Hybrid hepatocyte growth factor gene which has a high expression efficiency and expresses two heterotypes of hepatocyte growth factor
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
JP2005539031A (en) * 2002-08-16 2005-12-22 シエーリング アクチエンゲゼルシャフト Gene therapy for severe limb ischemia with wild-type or mutant eNOS
AU2008200822A1 (en) * 2002-08-22 2008-03-13 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
CN100366257C (en) * 2002-08-22 2008-02-06 克里夫兰诊所基金会 Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
CN1738638A (en) * 2002-12-13 2006-02-22 藤原久义 Medicinal composition for treating ischemic cardiac failure
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
WO2005107817A2 (en) * 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
CA2584553A1 (en) * 2004-09-17 2006-03-23 Cellgentech, Inc. External agent for treatment of skin ulcer
TW200637571A (en) * 2005-01-11 2006-11-01 Univ Nagoya Nat Univ Corp CSF-containing remedy to be administered in low dose
WO2006093172A1 (en) * 2005-02-28 2006-09-08 Foundation For Biomedical Research And Innovation Method for in vitro amplification of adult stem cells
ES2520044T3 (en) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 for use in the treatment of ischemic peripheral vascular disorders
WO2009062143A2 (en) 2007-11-09 2009-05-14 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium using cytokines and variants thereof
WO2009073616A2 (en) 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
WO2009073594A1 (en) 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
RU2470995C2 (en) 2008-04-09 2012-12-27 Вайромед Ко., Лтд. Lyophilised dna compounds for increased plasmid dna expression
JP5856059B2 (en) 2009-08-28 2016-02-09 ザ クリーブランド クリニック ファウンデーション SDF-1 delivery for treating ischemic tissue
WO2012148200A2 (en) * 2011-04-26 2012-11-01 아주대학교 산학협력단 Composition for aiding surgical procedures for treating ischemic vascular diseases
KR101609690B1 (en) * 2011-04-26 2016-04-06 아주대학교산학협력단 Surgical or Procedural Sub-composition for Treating Ischemic Vascular Disease
KR101336386B1 (en) * 2011-06-17 2013-12-04 전북대학교병원 Revellent lymph blood vessel
MX2016005006A (en) 2013-10-22 2016-07-14 Viromed Co Ltd Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor.
EP3266459A4 (en) * 2015-03-18 2018-04-18 Foundation for Biomedical Research and Innovation Medicine for treatment and/or prevention of ischemic diseases, method for improving angiogenesis-promoting activity of cells, or method for producing medicine
KR20210027493A (en) 2018-07-19 2021-03-10 주식회사 헬릭스미스 Freeze-dried pharmaceutical composition for naked DNA gene therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019712A1 (en) * 1996-11-08 1998-05-14 St. Elizabeth's Medical Center Of Boston, Inc. Methods for regulating angiogenesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808042A (en) * 1982-06-11 1989-02-28 Electro-Plasma, Inc. Powder feeder
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5880090A (en) * 1997-09-19 1999-03-09 The Hope Heart Institute Treatment of vascular graft implants with G-CSF

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998019712A1 (en) * 1996-11-08 1998-05-14 St. Elizabeth's Medical Center Of Boston, Inc. Methods for regulating angiogenesis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ASAHARA TAKAYUKI ET AL: "Vasculogenesis, developed by endothelial progenitor cells, has significant role in neovascularization in severe ischemia", CIRCULATION, vol. 96, no. 8 SUPPL., 21 October 1997 (1997-10-21), & 70TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION; ORLANDO, FLORIDA, USA; NOVEMBER 9-12, 1997, pages I415 - I416, XP008033796, ISSN: 0009-7322 *
FLAMME INGO ET AL: "Induction of vasculogenesis and hematopoiesis in vitro", DEVELOPMENT (CAMBRIDGE), vol. 116, no. 2, 1992, pages 435 - 439, XP002291992, ISSN: 0950-1991 *
KALKA C ET AL: "Angiogenese und Vaskulogenese", HERZ, URBAN UND VOGEL, MUENCHEN, DE, vol. 25, no. 6, 2000, pages 611 - 622, XP002971995, ISSN: 0340-9937 *
See also references of WO9945775A1 *

Also Published As

Publication number Publication date
JP2002506008A (en) 2002-02-26
WO1999045775A1 (en) 1999-09-16
AU766238B2 (en) 2003-10-09
CA2322559C (en) 2012-07-17
CA2322559A1 (en) 1999-09-16
EP1061800A1 (en) 2000-12-27
JP2010265301A (en) 2010-11-25
AU3073799A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
EP1061800A4 (en) Compositions and methods for modulating vascularization
GB9607897D0 (en) Organosiloxane compositions
PL327659A1 (en) Disinfecting compositions and surface disinfecting methods
CY2506B1 (en) Composition
GB9624874D0 (en) Composition
HUP9900960A3 (en) Disinfecting compositions and method for disinfecting surfaces
IL142725A0 (en) Method and composition for modulating amyloidosis
GB9601398D0 (en) Composition
GB9612595D0 (en) Composition
EP0880353A4 (en) Compositions and methods for modulating melanin production
EP1056456A4 (en) R-lansoprazole compositions and methods
EP1056457A4 (en) S-lansoprazole compositions and methods
GB9605247D0 (en) Composition
EP0884044A4 (en) Hairtreatment composition
GB9619074D0 (en) Composition
EP1073333A4 (en) S-rabeprazole compositions and methods
GB9600604D0 (en) Composition
GB9803506D0 (en) Composition and method
GB9602266D0 (en) Composition
GB9610966D0 (en) Composition
IL140574A0 (en) Methods and compositions for modulating spermatogenesis
EP1073332A4 (en) R-rabeprazole compositions and methods
ZA97698B (en) Composition
PL330421A1 (en) Antiprespirant composition
GB9604585D0 (en) Composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001009

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CARITAS ST. ELIZABETH'S MEDICAL CENTER OF BOSTON,

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 35/28 B

Ipc: 7A 61K 35/14 B

Ipc: 7A 61K 38/19 B

Ipc: 7A 61K 38/18 B

Ipc: 7C 12Q 1/00 B

Ipc: 7A 01N 37/18 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040823

17Q First examination report despatched

Effective date: 20060926

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160503